Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I SAD of PTI-125 in Healthy Volunteers
NCT03784300Phase 1Completed
- Sponsor
- Cassava Sciences
- Start
- Aug 2017
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of simufilam in Alzheimer's disease (AD) (6 arms), sponsored by Cassava Sciences. Primary endpoints: Maximum Plasma Concentration, Time to Maximum Plasma Concentration and 9 more. Started Aug 2017; status: completed.
02
Drugs
simufilam
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03784300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03784300.